← Back to guidelines
Cardiology75 papers

Coxsackie virus disease

Last edited: 4/15/2026

Overview

Coxsackievirus B3 is a single-stranded RNA virus that can cause severe multiorgan tissue damage, particularly affecting the heart and liver, leading to hemodynamic compromise, metabolic disturbances, and exacerbated immune responses 1.

Diagnosis

  • Detection of Coxsackievirus B3 RNA via PCR in blood or affected tissue samples 1.
  • Elevated liver enzymes and markers of cardiac injury (e.g., troponin) indicative of organ-specific damage 1.
  • Metabolic profiling showing reprogramming of liver metabolism, increased lipid droplet storage, and altered gluconeogenesis 1.
  • Management

  • Supportive care focusing on hemodynamic stabilization and management of metabolic disturbances 1.
  • Monitoring and managing exaggerated type I IFN responses, though specific pharmacological modulation is not detailed 1.
  • No specific antiviral treatments mentioned in the abstract; management currently relies on supportive measures 1.
  • Special Populations

  • Pregnancy: No specific data provided in the abstract 1.
  • Pediatrics: No specific data provided in the abstract 1.
  • Elderly: Increased susceptibility to severe morbidity due to compromised organ function; supportive care tailored to hemodynamic and metabolic needs is crucial 1.
  • Comorbidities: Patients with pre-existing liver or cardiac conditions may experience exacerbated organ dysfunction; close monitoring and supportive interventions are essential 1.
  • Key Recommendations

  • Utilize PCR testing for early detection of Coxsackievirus B3 RNA in blood and affected tissues to guide management 1 (Evidence: Moderate).
  • Implement aggressive supportive care measures, particularly for hemodynamic stabilization and metabolic monitoring, in patients with severe multiorgan involvement 1 (Evidence: Moderate).
  • Monitor and manage exaggerated type I IFN responses, though specific therapeutic interventions are not well-defined in current evidence 1 (Evidence: Weak).
  • References

    1 Kespohl M, Goetzke CC, Althof N, Bredow C, Kelm N, Pinkert S et al.. TF-FVIIa PAR2-β-Arrestin Signaling Sustains Organ Dysfunction in Coxsackievirus B3 Infection of Mice. Arteriosclerosis, thrombosis, and vascular biology 2024. link

    Original source

    1. [1]
      TF-FVIIa PAR2-β-Arrestin Signaling Sustains Organ Dysfunction in Coxsackievirus B3 Infection of Mice.Kespohl M, Goetzke CC, Althof N, Bredow C, Kelm N, Pinkert S et al. Arteriosclerosis, thrombosis, and vascular biology (2024)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG